Combined Therapy with vaccine and anti-CTLA-4 mAb enhanced CD8+ T cell infiltration of tumors (Fig. 3) by blocking CTLA-4, remodeling the immunosuppressive TME (Fig. 1 and Fig. 2) and normalizing tumor vasculature (Fig. 3). Here, CD8A is linked to neoplasm.